Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer

• Published in: Molecular cancer therapeutics Vol. 18; no. 1; pp. 196 - 203
• Main Authors: Wei, Tao, Zhang, Qi, Li, Xiang, Su, Wei, Li, Guogang, Ma, Tao, Gao, Shunliang, Lou, Jianying, Que, Risheng, Zheng, Lei, Bai, Xueli, Liang, Tingbo
• Format: Journal Article
• Language: English
• Published: United States 01.01.2019
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Pancreatic Ductal - drug therapy; Carcinoma, Pancreatic Ductal - genetics; Case-Control Studies; Circulating Tumor DNA - genetics; Female; Fluorouracil - pharmacology; Fluorouracil - therapeutic use; High-Throughput Nucleotide Sequencing - methods; Humans; Irinotecan - pharmacology; Irinotecan - therapeutic use; Leucovorin - pharmacology; Leucovorin - therapeutic use; Male; Middle Aged; Mutation; Oxaliplatin - pharmacology; Oxaliplatin - therapeutic use; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - genetics; Prospective Studies; Sequence Analysis, DNA; Treatment Outcome; Tumor Burden - drug effects

We aimed to explore the application of circulating cell-free DNA (cfDNA) profiling in monitoring tumor burden in patients with pancreatic ductal adenocarcinoma (PDAC). Thirty-eight patients with advanced PDAC receiving first-line FOLFIRINOX chemotherapy were prospectively enrolled. Next-generation s...